Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC
A Phase II Open-label, Single-arm Study Assessing the Efficacy and Safety of Combination Therapy of Sintilimab and Metformin With Relapsed PD-L1 Positive Small Cell Lung Cancer
Sponsor: Hunan Cancer Hospital
A PHASE2 clinical study on Small Cell Lung Cancer Extensive Stage and Small Cell Lung Cancer Recurrent, this trial is ongoing. The trial is conducted by Hunan Cancer Hospital and has accumulated 6 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Sep 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Sep 2022 [monthly]
Recruiting PHASE2
-
Sep 2019 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Jul 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hunan Cancer Hospital
- Innovent Biologics (Suzhou) Co. Ltd.
- Xiangya Hospital of Central South University
For direct contact, visit the study record on ClinicalTrials.gov .